Modular Medical, Inc. Common Stock (MODD) Stock Price
MODDStock
$2.31−86.10%52W
Market Cap$21.98M
P/E—
PEG Ratio—
Div yield—
Beta0.35
MODD Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-61.78%
Price vs S&P 500 (4W)3.76%
VGM Score20.67
MODD Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q4 2024 | -$3.60 | -$3.90 | -8.33%(-$0.30) | |
| Q3 2024 | -$3.30 | -$4.20 | -27.27%(-$0.90) | |
| Q2 2024 | -$5.55 | -$3.60 | +35.14%(+$1.95) | |
| Q1 2024 | -$6.00 | -$4.20 | +30.00%(+$1.80) |
MODD Analyst Recommendations
Feb 2025
Mar 2025
Apr 2025
May 2025
4.14
4.14
4.14
4.14
Industry Peers — Surgical & Medical Instruments(142)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
MODDModular Medical, Inc. Common Stock | — | — | D | — | — | — | — | $2.31 |
| SYKStryker Corporation | C | B | C | 4.4x | 11.8% | 65.3% | 21.3% | $294.66 |
| MMM3M Company | C | D | B | 3.4x | -5.0% | 39.4% | 18.4% | $164.75 |
| BSXBoston Scientific Corp. | C | B | C | 3.1x | 15.2% | 69.5% | 19.8% | $44.39 |
| BDXBecton, Dickinson and Co. | B | D | A | 2.5x | 6.3% | 46.7% | 9.6% | $191.75 |
| MDLNMedline Inc. Class A common stock | C | D | C | 1.6x | — | 26.2% | 6.0% | $35.96 |
| RMDResMed Inc. | C | C | B | 5.9x | 12.1% | 61.1% | 33.4% | $238.97 |
| DXCMDexCom, Inc. | C | B | B | 6.5x | 19.3% | 64.3% | 22.9% | $86.04 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | 8.5x | 7.4% | 36.8% | 20.4% | $384.02 |
| SOLVSolventum Corporation | C | C | B | 1.8x | — | 54.8% | 23.9% | $85.81 |
| BAXBaxter International Inc. | B | D | B | 1.1x | -0.8% | 30.7% | -2.3% | $25.28 |
About Modular Medical, Inc. Common Stock
Modular Medical Inc is a development-stage medical device company designing modernized insulin pumps for type 1 and type 2 diabetes markets. The company targets growth opportunities in insulin pump adoption through improved technology and user-centric design, with particular focus on the rapidly expanding type 2 diabetes segment.